 Umeclidinium bromide (TOP), vilanterol (BOTTOM) | |
| Combination of | |
|---|---|
| Umeclidinium bromide | Muscarinic antagonist |
| Vilanterol | Ultra-long-acting β2 agonist |
| Clinical data | |
| Trade names | Anoro Ellipta, Laventair Ellipta |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category |
|
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Umeclidinium bromide/vilanterol, sold under the brand name Anoro Ellipta, among others, is a fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease (COPD).[4][5] It is administered by inhalation.
The most common side effects include upper respiratory tract infections, urinary tract infections, pharyngitis, sinusitis, nasopharyngitis, headache, cough, oropharyngeal pain, constipation and dry mouth.[3]
In 2021, it was the 212th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[6][7]
YouTube Encyclopedic
-
1/5Views:35 209101 090120 48852 4411 685
-
How to use Ellipta inhaler (Trelegy, Relvar, Anoro, Breo, Incruse)
-
FPA Network -Ellipta Demo
-
How to Use an Ellipta Inhaler
-
5. How to use inhalers - Ellipta (Incruse, Anoro, Relvar, Trelegy, Breo)
-
When are inhaled corticosteroids used in COPD?
Transcription
References
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ "Anoro Ellipta 55 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC)". (emc). 7 October 2019. Retrieved 29 October 2020.
- ^ a b "Anoro Ellipta EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 28 October 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659. S2CID 5744282.
- ^ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. 18 December 2013.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Umeclidinium; Vilanterol - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
| Subsidiaries |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Predecessors, acquisitions | |||||||||
| Products |
| ||||||||
| People |
| ||||||||
| Litigation | |||||||||
| Other | |||||||||
| |||||||||
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 2 March 2024, at 06:46